How the Covid-19 vaccine crisis is putting the EU in danger

The botched coronavirus vaccine campaign will cause long-term harm to the EU's economy, says Matthew Lynn.

Export controls may be imposed. Supplies are being held up at factories. Police in Italy are carrying out raids, looking for any evidence of stock being withheld or sent abroad. The grim farce of the European Union’s coronavirus vaccine crisis has taken twist after twist. 

Supplies will soon pick up: so much has been ordered that the developed world at least will be awash with vaccines. The continent will finally be able to get on with inoculating its citizens by summer. But this will not end the long-term consequences of this crisis. They will run and run. 

A catastrophe from the start

The EU’s vaccination campaign has been a catastrophe. The European Commission hijacked procurement, bought the wrong vaccines, in the wrong quantities, put itself at the back of the queue, and failed to invest in ramping up production. It dithered and delayed over the approvals process. Its leaders cast doubts on the effectiveness of the one jab that was available in large quantities. Regulators suspended it on the flimsiest of evidence, holding up the roll-out for several days for no reason. 

The statistics make it clear how badly this has gone. While the UK has given over half the adult population at least one shot, with the United States not far behind, major European countries such as France, Italy, Spain and Germany are still on less than 10%. So while infections, and more importantly deaths and hospitalisations, are collapsing in the UK and the US, Europe is going back into another lockdown. 

That means economies will be shut for far longer than they otherwise would have been. Israel has opened up, the US is following behind, and Britain will start getting back to normal this month. Shops, restaurants and gyms will all welcome customers again. By contrast, Germany, France and Italy are all imposing fresh restrictions, meaning the recession will drag on for at least another three months, and governments will have to run up more debt to pay for it. Lost output will eventually be recovered as the virus comes under control, but the debt will stick around. 

The EU has also done huge damage to its reputation. As it panics over the supply of vaccines, the Commission has trashed property rights and suspended the rule of law. It has seized supplies and blocked companies from exporting with, so far as anyone can tell, no right of appeal, or any form of due process. There is simply bureaucratic fiat deciding who you can sell to and who you can’t. 

Vaccine manufacturing, a major industry for the EU, is going to suffer. Every sensible government is going to make sure it has its own plants, given that it now knows in a pandemic the EU will seize factories. But the effects will go further than that. Every manufacturer will be wondering what might happen to their production lines in an emergency and may conclude the EU is not a safe place to invest anymore.

Expect political chaos

Finally, it will unleash political chaos. Ursula von der Leyen, the president of the European Commission, is now surely a lame duck. There is no mechanism for getting rid of her, but she won’t be able to drive through any new programmes. That matters. The EU still needs to get its vaccination programme back on track. It needs to implement that Coronavirus Rescue Fund to stimulate devastated economies in southern Europe. Beyond that, there is still the task of restoring the zone’s competitiveness. But it is unlikely anyone will be listening to her now.

Meanwhile German elections in the autumn may sweep the Greens to power at the head of a ramshackle coalition. In France, it is hard to see Emmanuel Macron winning reelection next spring if he can’t get the virus under control. In Italy, Mario Draghi may not survive long if he can’t get jabs into people’s arms. Europe is about to go through a year of intense political uncertainty. It was already the least-attractive region in the world for investors. The vaccine crisis has made perceptions far worse. Recovery could take years.

Recommended

Britain’s ten most-hated shares – w/e 1 July
Stocks and shares

Britain’s ten most-hated shares – w/e 1 July

Rupert Hargreaves looks at Britain's ten most-hated shares, and what short-sellers are looking at now.
4 Jul 2022
Britain’s most-bought shares w/e 1 July
Stocks and shares

Britain’s most-bought shares w/e 1 July

A look at Britain’s most-bought shares in the week ending 1 July, providing an insight into how investors are thinking and where opportunities may lie…
4 Jul 2022
M&G offers a solid 10.1% yield – but future growth is uncertain
Share tips

M&G offers a solid 10.1% yield – but future growth is uncertain

Financial services group M&G has one of the highest dividend yields in the FTSE 100. But it’s a complicated company, and a tough one to analyse, says …
4 Jul 2022
We’re doing well on pensions – but we still need to do better
Pensions

We’re doing well on pensions – but we still need to do better

Pensions auto-enrolment has vastly increased the number of people in the UK with retirement savings. But we’re still not engaged enough, says Merryn S…
4 Jul 2022

Most Popular

Ray Dalio’s shrewd $10bn bet on the collapse of European stocks
European stockmarkets

Ray Dalio’s shrewd $10bn bet on the collapse of European stocks

Ray Dalio’s Bridgewater hedge fund is putting its money on a collapse in European stocks. It’s likely to pay off, says Matthew Lynn.
3 Jul 2022
UK house prices are definitely cooling off – but are they heading for a fall?
House prices

UK house prices are definitely cooling off – but are they heading for a fall?

UK house prices hit a fresh high in June, but as interest rates start to rise, the market is cooling John Stepek assesses just how much of an effect h…
30 Jun 2022
Persimmon yields 12.3%, but can you trust the company to deliver?
Share tips

Persimmon yields 12.3%, but can you trust the company to deliver?

With a dividend yield of 12.3%, Persimmon looks like a highly attractive prospect for income investors. But that sort of yield can also indicate compa…
1 Jul 2022